Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort-Reference-Cited by-同舟云学术

Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort

Published:2023-09 Issue:7 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Steenbruggen Tessa G.¹²^ORCID,Wolf Denise M.²,Thijssen Bram³,Sanders Joyce⁴^ORCID,Cornelissen Sten⁵,Salgado Roberto⁶⁷^ORCID,Mittempergher Lorenza⁸^ORCID,Bhaskaran Rajith⁸,Broeks Annegien⁵^ORCID,Lips Esther H.⁹,Siesling Sabine¹⁰¹¹^ORCID,Sonke Gabe S.¹^ORCID,Horlings Hugo M.⁴^ORCID,van ’t Veer Laura J.²

Affiliation:

1. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

2. Department of Laboratory Medicine, University of California, San Francisco, CA

3. Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands

4. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

5. Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands

6. Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium

7. Division of Research, Peter Mac Callum Cancer Centre, Melbourne, VIC, Australia

8. Research and Development, Agendia NV, Amsterdam, the Netherlands

9. Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

10. Department of Research and Development, Netherlands Comprehensive Cancer Organisation, (IKNL), Utrecht, the Netherlands

11. Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands

Abstract

Extracellular-matrix features distinguish between long-term versus shorter-term survivors with OligoMBC.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.22.00670

Reference35 articles.

1. Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer

2. Oligometastases.

3. The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease

4. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial

5. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).